TWI868106B - 安全投予磷酸化Tau胜肽疫苗的方法 - Google Patents
安全投予磷酸化Tau胜肽疫苗的方法 Download PDFInfo
- Publication number
- TWI868106B TWI868106B TW109104093A TW109104093A TWI868106B TW I868106 B TWI868106 B TW I868106B TW 109104093 A TW109104093 A TW 109104093A TW 109104093 A TW109104093 A TW 109104093A TW I868106 B TWI868106 B TW I868106B
- Authority
- TW
- Taiwan
- Prior art keywords
- seq
- nmole
- tau
- per dose
- liposomes
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962802870P | 2019-02-08 | 2019-02-08 | |
| US62/802,870 | 2019-02-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202045204A TW202045204A (zh) | 2020-12-16 |
| TWI868106B true TWI868106B (zh) | 2025-01-01 |
Family
ID=69780323
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW109104093A TWI868106B (zh) | 2019-02-08 | 2020-02-10 | 安全投予磷酸化Tau胜肽疫苗的方法 |
Country Status (17)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| TW202333768A (zh) * | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| KR20210124308A (ko) | 2019-01-30 | 2021-10-14 | 트루바인딩 아이엔씨. | 항-gal3 항체 및 이의 용도 |
| SG11202108312PA (en) | 2019-02-08 | 2021-08-30 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
| CN114728169A (zh) * | 2019-09-23 | 2022-07-08 | 麦考瑞大学 | tau蛋白病的治疗 |
| MX2022014786A (es) | 2020-05-26 | 2023-01-16 | Truebinding Inc | Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3. |
| GB2600468A (en) * | 2020-10-30 | 2022-05-04 | Excivion Ltd | Adjuvant composition |
| KR20240042508A (ko) * | 2021-08-12 | 2024-04-02 | 얀센 파마슈티칼즈, 인코포레이티드 | 지속적인 면역 반응을 유도하기 위한 인산화 타우 펩티드를 함유하는 리포솜 |
| US20250134991A1 (en) * | 2021-08-20 | 2025-05-01 | Thomas Jefferson University | Monophosphoryl lipid adjuvant (mpla) compositions, vaccine compositions thereof, and methods of preparing and using the same |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232758A1 (en) * | 2002-04-19 | 2003-12-18 | Hospital For Sick Children And University Of Toronto | Immunological methods and compositions for the treatment of Alzheimer's disease |
| US20120183599A1 (en) * | 2009-04-03 | 2012-07-19 | Ac Immune S.A. | Pharmaceutical Composition |
Family Cites Families (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5811310A (en) | 1986-09-30 | 1998-09-22 | Albert Einstein College Of Medicine Of Yeshiva Univ. | The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease |
| WO1990014837A1 (en) | 1989-05-25 | 1990-12-13 | Chiron Corporation | Adjuvant formulation comprising a submicron oil droplet emulsion |
| US7408027B1 (en) | 1991-12-06 | 2008-08-05 | Max-Planck-Gesellschaft Zur Forderung Der Wissenchaften | Tools for the diagnosis and treatment of Alzheimer's disease |
| AU690092B2 (en) | 1992-12-14 | 1998-04-23 | N.V. Innogenetics S.A. | Monoclonal antibodies directed against the microtubule-associated protein tau, hybridomas secreting these antibodies, antigen recognition by these monoclonal antibodies and their applications |
| US7427392B1 (en) | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| WO1997034145A1 (fr) | 1996-03-13 | 1997-09-18 | Mitsubishi Chemical Corporation | Anticorps a proteine tau antiphosphorylee et procede de detection de la maladie d'alzheimer l'utilisant |
| WO1998022120A1 (en) | 1996-11-19 | 1998-05-28 | The Wistar Institute Of Anatomy & Biology | Diagnostic and therapeutic reagents for alzheimer's disease |
| EA003739B1 (ru) | 1997-12-03 | 2003-08-28 | Байоджен, Инк. | Гидрофобно-модифицированные белки, способы их получения и их применение |
| US6314469B1 (en) | 1999-02-26 | 2001-11-06 | I-Dns.Net International Pte Ltd | Multi-language domain name service |
| AU2001273361A1 (en) | 2000-07-11 | 2002-01-21 | Molecular Geriatrics Corporation | Reagents and methods for identification of binding agents |
| GB0114719D0 (en) * | 2001-06-15 | 2001-08-08 | Glaxo Group Ltd | Compound |
| AU2003203079B9 (en) | 2002-02-04 | 2009-01-15 | Oncothyreon Inc. | Immunostimulatory, covalently lipidated oligonucleotides |
| KR20050101537A (ko) | 2002-12-24 | 2005-10-24 | 뉴로켐 (인터내셔널) 리미티드 | 베타-아밀로이드 관련 질환의 치료를 위한 치료 제제 |
| US8663650B2 (en) | 2003-02-21 | 2014-03-04 | Ac Immune Sa | Methods and compositions comprising supramolecular constructs |
| WO2005058137A2 (en) | 2003-12-12 | 2005-06-30 | University Of Washington | Catheterscope 3d guidance and interface system |
| US20050261475A1 (en) | 2004-02-13 | 2005-11-24 | Harvard Medical School | Solid-phase capture-release-tag methods for phosphoproteomic analyses |
| US7238788B2 (en) | 2004-02-18 | 2007-07-03 | University Of Iowa Foundation | Antibodies to phosphorylated tau, methods of making and methods of use |
| WO2006121656A2 (en) | 2005-05-05 | 2006-11-16 | Merck & Co., Inc. | Peptide conjugate compositions and methods for the prevention and treatment of alzheimer's disease |
| CA2633399C (en) | 2005-12-12 | 2016-01-26 | Ac Immune S.A. | Therapeutic vaccine |
| WO2007068105A1 (en) | 2005-12-12 | 2007-06-21 | Robarts Research Institute | Method of diagnosing amyotrophic lateral sclerosis |
| EP2514824A3 (en) | 2006-03-03 | 2013-01-23 | Amorfix Life Sciences Ltd. | Methods and compositions to treat and detect misfolded-SOD1 mediated diseases |
| US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
| US20080220449A1 (en) | 2007-02-08 | 2008-09-11 | Oligomerix, Inc. | Biomarkers and assays for Alzheimer's disease |
| KR20100115340A (ko) | 2007-10-19 | 2010-10-27 | 이무나스 파마 가부시키가이샤 | Aβ 올리고머에 특이적으로 결합하는 항체 및 그의 이용 |
| US9498522B2 (en) | 2008-08-07 | 2016-11-22 | Mercia Pharma Inc. | Immunotherapeutic compositions for the treatment of alzheimer'S disease |
| CN102365295A (zh) | 2009-01-30 | 2012-02-29 | 阿德利夫股份有限公司 | 构象动力肽 |
| US9605054B2 (en) | 2009-02-23 | 2017-03-28 | The Board Of Trustees Of The University Of Illinois | Composition and method for treating a tauopathy |
| MX2011009654A (es) | 2009-03-18 | 2011-10-12 | Ac Immune Sa | Metodo para uso terapeutico. |
| EP4218794A3 (en) | 2009-06-10 | 2023-09-13 | New York University | Immunological targeting of pathological tau proteins |
| CN102596236B (zh) | 2009-07-30 | 2015-06-24 | 辉瑞疫苗有限责任公司 | 抗原性Tau肽及其用途 |
| AU2010291933B2 (en) | 2009-09-14 | 2016-09-08 | Banyan Biomarkers, Inc. | Micro-RNA, autoantibody and protein markers for diagnosis of neuronal injury |
| KR20130103662A (ko) | 2010-04-19 | 2013-09-24 | 엔라이프 떼라퓨틱스, 에스.엘. | 올리고뉴클레오티드 분자들의 특정 뉴런 유형들로의 선택적인 전달을 위한 조성물들 및 방법 |
| WO2012020124A1 (en) | 2010-08-12 | 2012-02-16 | Ac Immune S.A. | Vaccine engineering |
| EP2632434B1 (en) | 2010-10-26 | 2025-08-20 | AC Immune S.A. | Liposome-based construct comprising a peptide modified through hydrophobic moieties |
| SI2675480T1 (sl) | 2011-02-15 | 2019-05-31 | Immunogen, Inc. | Metode priprave konjugatov |
| EP3275461A1 (en) | 2011-09-19 | 2018-01-31 | Axon Neuroscience SE | Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease field |
| CA2811188C (en) | 2011-09-23 | 2020-04-28 | Andrea Pfeifer | Vaccine therapy |
| WO2013058350A1 (ja) | 2011-10-21 | 2013-04-25 | 三菱化学株式会社 | 周期表第13族金属窒化物半導体結晶の製造方法、及び該製造方法により製造される周期表第13族金属窒化物半導体結晶 |
| EP2659906A1 (en) | 2012-05-01 | 2013-11-06 | Affiris AG | Compositions |
| US20140056901A1 (en) | 2012-08-21 | 2014-02-27 | The Institute For Molecular Medicine | Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies |
| WO2014165271A2 (en) | 2013-03-13 | 2014-10-09 | Neotope Biosciences Limited | Tau immunotherapy |
| CN105939722A (zh) | 2014-02-14 | 2016-09-14 | 伊皮埃里安股份有限公司 | Tau肽,抗Tau抗体,及其使用方法 |
| CA2952741A1 (en) | 2014-06-26 | 2015-12-30 | Janssen Vaccines & Prevention B.V. | Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau |
| NZ775762A (en) | 2015-06-05 | 2025-02-28 | Genentech Inc | Anti-tau antibodies and methods of use |
| CA2988436A1 (en) | 2015-07-13 | 2017-01-19 | Arvinas, Inc. | Alanine-based modulators of proteolysis and associated methods of use |
| EP4657376A3 (en) | 2015-08-14 | 2026-03-04 | Intuitive Surgical Operations, Inc. | Systems and methods of registration for image-guided surgery |
| MX2018013384A (es) | 2016-05-02 | 2019-02-28 | Prothena Biosciences Ltd | Anticuerpos que reconocen tau. |
| EP3551220B1 (en) | 2016-12-07 | 2025-01-29 | Genentech, Inc. | Anti-tau antibodies and methods of use |
| TW202333768A (zh) | 2017-10-25 | 2023-09-01 | 美商健生醫藥公司 | Tau胜肽之組成物及其用途 |
| CN111587123A (zh) | 2017-11-09 | 2020-08-25 | 品通治疗有限公司 | 用于生成和使用人源化构象特异性磷酸化的τ抗体的方法和组合物 |
| SG11202108312PA (en) | 2019-02-08 | 2021-08-30 | Ac Immune Sa | Method of safe administration of phosphorylated tau peptide vaccine |
| MX2021012994A (es) | 2019-04-24 | 2022-03-04 | Janssen Pharmaceuticals Inc | Administracion heterologa de vacunas tau. |
-
2020
- 2020-02-07 SG SG11202108312PA patent/SG11202108312PA/en unknown
- 2020-02-07 CA CA3129252A patent/CA3129252A1/en active Pending
- 2020-02-07 MX MX2021009508A patent/MX2021009508A/es unknown
- 2020-02-07 WO PCT/US2020/017235 patent/WO2020163730A2/en not_active Ceased
- 2020-02-07 EA EA202192203A patent/EA202192203A1/ru unknown
- 2020-02-07 EP EP20710370.6A patent/EP3920966A2/en active Pending
- 2020-02-07 CN CN202080027380.1A patent/CN113710269A/zh active Pending
- 2020-02-07 PH PH1/2021/551876A patent/PH12021551876A1/en unknown
- 2020-02-07 US US16/785,011 patent/US11684576B2/en active Active
- 2020-02-07 JO JOP/2021/0211A patent/JOP20210211A1/ar unknown
- 2020-02-07 MY MYPI2021004512A patent/MY206596A/en unknown
- 2020-02-07 AU AU2020219804A patent/AU2020219804A1/en active Pending
- 2020-02-07 KR KR1020217028336A patent/KR20210125048A/ko active Pending
- 2020-02-07 JP JP2021546263A patent/JP7541527B2/ja active Active
- 2020-02-07 BR BR112021014794-2A patent/BR112021014794A2/pt unknown
- 2020-02-07 IL IL285163A patent/IL285163B2/en unknown
- 2020-02-10 TW TW109104093A patent/TWI868106B/zh active
-
2023
- 2023-05-12 US US18/316,829 patent/US12324855B2/en active Active
-
2024
- 2024-08-16 JP JP2024136910A patent/JP2024178161A/ja active Pending
-
2025
- 2025-05-22 US US19/216,215 patent/US20250275920A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030232758A1 (en) * | 2002-04-19 | 2003-12-18 | Hospital For Sick Children And University Of Toronto | Immunological methods and compositions for the treatment of Alzheimer's disease |
| US20120183599A1 (en) * | 2009-04-03 | 2012-07-19 | Ac Immune S.A. | Pharmaceutical Composition |
Non-Patent Citations (1)
| Title |
|---|
| 期刊 Brandon Kwong et al. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 32(22) Epub 2011 Apr 22. 5134-5147. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113710269A (zh) | 2021-11-26 |
| US12324855B2 (en) | 2025-06-10 |
| PH12021551876A1 (en) | 2022-05-23 |
| US20230381108A1 (en) | 2023-11-30 |
| IL285163B2 (en) | 2025-05-01 |
| BR112021014794A2 (pt) | 2021-10-05 |
| AU2020219804A1 (en) | 2021-08-19 |
| IL285163A (en) | 2021-09-30 |
| SG11202108312PA (en) | 2021-08-30 |
| US11684576B2 (en) | 2023-06-27 |
| IL285163B1 (en) | 2025-01-01 |
| US20200253873A1 (en) | 2020-08-13 |
| JP2024178161A (ja) | 2024-12-24 |
| JOP20210211A1 (ar) | 2023-01-30 |
| JP7541527B2 (ja) | 2024-08-28 |
| JP2022520060A (ja) | 2022-03-28 |
| EP3920966A2 (en) | 2021-12-15 |
| US20250275920A1 (en) | 2025-09-04 |
| KR20210125048A (ko) | 2021-10-15 |
| CA3129252A1 (en) | 2020-08-13 |
| EA202192203A1 (ru) | 2021-10-20 |
| MY206596A (en) | 2024-12-25 |
| TW202045204A (zh) | 2020-12-16 |
| MX2021009508A (es) | 2021-09-08 |
| WO2020163730A3 (en) | 2020-09-24 |
| WO2020163730A2 (en) | 2020-08-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12324855B2 (en) | Method of safe administration of phosphorylated Tau peptide vaccine | |
| JP7617852B2 (ja) | タウワクチンの異種投与 | |
| CN117298259A (zh) | 磷酸化Tau肽的组合物及其用途 | |
| US20250144212A1 (en) | Liposomes containing phosphorylated tau peptides for inducing sustained immune responses | |
| HK40061379A (en) | Method of safe administration of phosphorylated tau peptide vaccine | |
| EA050855B1 (ru) | ЛИПОСОМА ДЛЯ ПРИМЕНЕНИЯ В СПОСОБЕ ИНДУКЦИИ АНТИТЕЛ К ФОСФОРИЛИРОВАННОМУ ПЕПТИДУ Tau | |
| US20250049900A1 (en) | Method of safe administration of tau phosphopeptide conjugate | |
| EA045311B1 (ru) | Способ безопасного введения вакцины фосфорилированного пептида tau | |
| EA051841B1 (ru) | Липосомы, содержащие фосфорилированные тау-пептиды, для индукции стойких иммунных ответов | |
| CN118159289A (zh) | 用于诱导持续免疫反应的含有磷酸化Tau肽的脂质体 | |
| JP2024532787A5 (cg-RX-API-DMAC7.html) |